Barclays analyst Luke Sergott raised the firm’s price target on Sotera Health (SHC) to $18 from $17 and keeps an Overweight rating on the shares. The firm says “no news is good news” on litigation as the California case count holds steady at 18.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue